| Hans-Günter Meyer-Thompson | Buprenorphin
CHMP recommends approval of Buvidal® (CAM2038) for the treatment of opioid dependence
CHMP recommends approval of Buvidal® (CAM2038) for the treatment of opioid dependence
On approval, Buvidal® would be the first long-acting medicine for treatment of opioid dependence in the EU
A final decision by the European Commission is expected November 2018. (Camurus, 21.09.2018)